BioLASCO Taiwan , Ltd.'s receivables is $40M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2026), 6662.TWO shows a receivables of $40M. That compares with $41M in the prior-year period — down 1.5% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, 6662.TWO's receivables is now $40M (was $41M) — a 1.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether BioLASCO Taiwan , Ltd. is outperforming or lagging.
Tracking 6662.TWO's receivables over time shows whether BioLASCO Taiwan , Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $40M That compares with $41M in the prior-year period — down 1.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this receivables page, Stockcircle has BioLASCO Taiwan , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $40M) with ownership activity and broader fundamentals.
BioLASCO Taiwan , Ltd.'s receivables is $40M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.